newsfilter
← Latest News
GlobeNewswire·

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

  • Aclarion reported 85% year-over-year scan volume growth in Q3 2026 & 117% growth for the nine months ended September 30, 2026.
  • Peer-reviewed data supporting Magnetic Resonance Spectroscopy (MRS) as a viable alternative to provocative discography was published in the European Spine Journal.
  • The CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment for the 300-patient study.
  • The CLARITY trial remains on track with an anticipated update on enrollment progress & initial readout timing by year-end 2026.
  • The company holds $14.2 million in cash, providing a runway into the second half of 2027 to fully fund the CLARITY trial.
  • Continued commercial traction & an expanding evidence base are expected to support reimbursement initiatives in the United Kingdom & United States.